Patrick Daly

DocwireNews

Exploratory findings have suggested that ryanodine receptor-driven intracellular calcium leak is a mediator of atrial fibrillation. In a study led by co-first authors, M. Benjamin Shoemaker and Zachary T. Yonenda, researchers investigated whether (R)-propafenone, an antiarrhythmic drug and ryanodine receptor inhibitor, was effective at preventing atrial fibrillation induction during ablation procedures when compared with (S)-propafenone or placebo.The study&rsquo;s authors found that there was no difference in atrial fibrillation induction between <a href="https://medlineplus.gov/druginfo/meds/a698002.html" target="_blank" rel="noopener">(R)-propafenone</a> and&nbsp;(S)-propafenone, though they added that their conclusions were subject to limitations. Their results were published in Circulation: Arrhythmia and Electrophysiology.<h3>Propafenone Enantiomers Show Similar Atrial Fibrillation Induction Prevention</h3>The study enrolled 193 patients with atrial fibrillation <a href="https://www.docwirenews.com/pocn-cardiology/coa-versus-tca-ablation-techniques-for-af/">referred for ablation</a>, of which 165 (median years of age, 63; 58% male, 95% paroxysmal atrial fibrillation) completed the trial. The cohort was randomized 4:4:1 to a single intravenous dose of (R)-propafenone, (S)-propafenone, or placebo administered at the start of ablation procedures with atrial fibrillation induction using rapid atrial pacing. The primary end point of the study was incidence of 30 seconds of atrial fibrillation or atrial flutter.According to the report, sustained atrial fibrillation and atrial flutter episodes were observed in 60 (80.0%) patients in the (R)-propafenone group, 60 (80.0%) in the (S)-propafenone group, and 12 (63.2%) in the placebo group. Notably, atrial flutter was reported significantly more often in the (R)- (n=23; 32.4%) and (S)-propafenone (n=26; 34.7%) groups compared with placebo (n=1; 5.3%; P=.029)Overall, the researchers did not find any significant differences in the primary atrial fibrillation and atrial flutter outcomes between the (R)- and (S)-propafenone groups in both univariable (P=.522) and multivariable analysis adjusted for age and serum drug level (P=.199).The authors ultimately summarized that &ldquo;there is no difference in AF inducibility between&nbsp;(R)- and (S)-propafenone at clinically relevant concentrations.&rdquo; They did acknowledge that the results were &ldquo;confounded by a high rate of inducible atrial flutter due to sodium-channel blockade.&rdquo;Find More <a href="https://www.docwirenews.com/atrial-fibrillation/">Related Research on the Atrial Fibrillation Knowledge Hub</a>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Propafenone to Prevent AF Induction During Ablation

Atrial Fibrillation

Exploratory findings have suggested that ryanodine receptor-driven intracellular calcium leak is a mediator of atrial fibrillation. In a study led by co-first authors, M. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe